Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions HIV Infections, Pregnancy Related, Depre...
Phase NA
Enrollment 165
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to develop a multi-level PrEP adherence and persistence intervention as an adaptation of the TENDAI ('grateful' in Shona) program, a problem-solving approach to reduce depression and increase HIV treatment adherence among people living with HIV in Zimbabwe. The new intervention, TENDAI4PrEP, will be designed to improve PrEP uptake and persistence among pregnant persons in Zimbabwe. If feasibility, acceptability, and preliminary efficacy are demonstrated, the intervention will be ready for large-scale effectiveness/implementation testing. This program will has the potential to address a critical public health challenge impacting pregnant and postpartum persons in Zimbabwe: the prevention of HIV acquisition and transmission.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: TENDAI4PrEP — An adapted problem-solving PrEP use intervention for HIV negative pregnant persons living with psychological distress, their partners, and antenatal care providers.
  • Other: Enhanced treatment as usual — Includes monthly visits to the ANC plus a pamphlet of information that describes PrEP efficacy. safety during pregnancy/postpartum, and PrEP availability at the ANC.

Primary Outcomes

  • Feasibility (patient level) (T3 (within 5 months post-baseline))
  • Acceptability (patient level) (T3 (within 5 months post-baseline))
  • Feasibility (provider level) (T3 (within 5 months post-baseline))
  • Acceptability (provider level) (T3 (within 5 months post-baseline))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-21
Completion: 2027-03-31
Eligibility
Age: 15 Years – 55 Years
Sex: ALL
Volunteers: false
Enrollment: 165 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: University of Zimbabwe, Boston University
Principal Investigators:
  • Amelia M Stanton, PhD (PRINCIPAL_INVESTIGATOR) - Boston University
  • Walter Mangezi, MD (PRINCIPAL_INVESTIGATOR) - University of Zimbabwe
Contact Information
Study Contact:
Conall O'Cleirigh
617-643-0385
cocleirigh@mgh.harvard.edu
Walter Mangezi, MD
+263712606560
wmangezi@yahoo.co.uk
University of Zimbabwe
Walter Mangezi, MD
University of Zimbabwe
Interventions
  • Behavioral: TENDAI4PrEP — An adapted problem-solving PrEP use intervention for HIV negative pregnant persons living with psychological distress, their partners, and antenatal care providers.
  • Other: Enhanced treatment as usual — Includes monthly visits to the ANC plus a pamphlet of information that describes PrEP efficacy. safety during pregnancy/postpartum, and PrEP availability at the ANC.
Study Locations (1 sites)
University of Zimbabwe, Harare, Zimbabwe
Eligibility Criteria
Inclusion Criteria: Across all aims participants must be 1. Pregnant 2. Presenting at the Chitungwiza Central Hospital ANC 3. Aged 15+ 4. Willing to provide informed consent or assent 5. Have HIV negative status 6. At risk for HIV acquisition (defined as having a male partner of unknown HIV status, suspicions of partner infidelity, reporting multiple partners, or history of STI and/or recent condomless sexual activity) 7. Score \>5 on the Shona Symptom Questionnaire For the RCT, eligible participants must also be willing to 8. Initiate PrEP prior to randomization 9. Bring their pregnancy partner (if they are safe doing so). Exclusion Criteria: 1. Inability to provide informed consent/assent and/or complete procedures in Shona or English 2. Current interfering untreated or unstable mental health condition that precludes functional involvement in the study (e.g., active psychosis, untreated bipolar disorder)
Conditions Anxiety, Hospitalization, Quality of Lif...
Phase NA
Enrollment 60
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Long hospital stays can be difficult for older adults. Being confined to a ward, with limited mobility and little access to the outdoors, may contribute to anxiety, low mood, and reduced well-being. Contact with nature is known to support relaxation and emotional recovery, but hospitalized patients often cannot go outside. This study compares two ways of bringing a nature experience to patients who are staying in hospital. In the first approach, participants wear a virtual reality headset and watch 360-degree videos filmed in real natural settings near Budapest: a meadow, a stream, and a mountain. The nature scene reaches them through their eyes and ears. In the second approach, participants listen to a short recorded audio guide and picture the same three nature scenes in their own minds, with their eyes closed. Here the nature scene is created by their own imagination. Both approaches use exactly the same nature themes. The only difference is how the experience reaches the person: from the outside through the senses, or from the inside through imagination. The study asks whether these two routes have different effects, and whether they can be told apart by measuring heart rate variability, which reflects how the body's automatic nervous system responds. Participants are adults aged 65 or older who have been in hospital for at least two weeks. After joining the study, each participant is first observed for two weeks while receiving only their usual hospital care. This period serves as their own comparison. They are then assigned by chance to one of the two approaches and take part in three sessions over two weeks. Questionnaires and brief cognitive tests are completed at three points: when joining, before the sessions begin, and after the sessions end. The main question is whether anxiety symptoms decrease more during the session period than during the preceding period of usual care. The study also looks at mood, attention and memory, well-being, and resilience.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Device: Immersive virtual reality nature exposure — Three sessions of 360-degree nature video viewed through a head-mounted display, delivered over two weeks. Videos were produced by the research team from a fixed tripod perspective at three locations near Budapest, corresponding to the motifs of meadow, stream, and mountain. They contain no narration or added music, only the natural soundscape of the location, and the viewpoint changes every five minutes. Exposure length ranges from 8 to 20 minutes according to participant tolerance. Sessions are conducted at the bedside under supervision, with the device used offline.
  • Behavioral: Guided imagery — Three sessions of guided imagery delivered over two weeks. Participants listen through headphones, with eyes closed, to a standardized five-minute audio recording that begins with a brief breathing relaxation followed by the motif text. The motifs are identical to those presented in the virtual reality arm and are drawn from the motif repertoire of Katathym Imaginative Psychotherapy. After each session, participants give a free verbal account of their experience.

Primary Outcomes

  • Heart rate variability during intervention sessions relative to resting and cognitive-load recordings (RMSSD) (Baseline through Week 4 (resting recording during the usual care period; cognitive load at baseline and Week 2; intervention sessions from Week 2 through Week 4))
  • Primary Outcome 1 - HADS-A (Baseline, Week 2, and Week 4.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-01
Completion: 2027-01
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Semmelweis University
Principal Investigators:
  • Xenia Gonda, MA, PharmD, PhD (PRINCIPAL_INVESTIGATOR) - Semmelweis University, Department of Psychiatry and Psychotherapy
Contact Information
Study Contact:
Patricia Lajko, MA
+36309874988
lajko.patricia@semmelweis.hu
Xenia Gonda, MA, PharmD, PhD
+36 1 235 6500
gonda.xenia@semmelweis.hu
Patricia Lajko, MA
+36309874988
lajko.patricia@semmelweis.hu
Semmelweis University, Department of Geriatrics and Nursing Science
Interventions
  • Device: Immersive virtual reality nature exposure — Three sessions of 360-degree nature video viewed through a head-mounted display, delivered over two weeks. Videos were produced by the research team from a fixed tripod perspective at three locations near Budapest, corresponding to the motifs of meadow, stream, and mountain. They contain no narration or added music, only the natural soundscape of the location, and the viewpoint changes every five minutes. Exposure length ranges from 8 to 20 minutes according to participant tolerance. Sessions are conducted at the bedside under supervision, with the device used offline.
  • Behavioral: Guided imagery — Three sessions of guided imagery delivered over two weeks. Participants listen through headphones, with eyes closed, to a standardized five-minute audio recording that begins with a brief breathing relaxation followed by the motif text. The motifs are identical to those presented in the virtual reality arm and are drawn from the motif repertoire of Katathym Imaginative Psychotherapy. After each session, participants give a free verbal account of their experience.
Study Locations (2 sites)
Semmelweis University, Department of Geriatrics and Nursing Science, Budapest, 1097 Hungary
Semmelweis University, Department of Rehabilitation Medicine, Budapest, 1121 Hungary
Eligibility Criteria
Inclusion Criteria: * Aged 65 years or older * Receiving inpatient hospital care, with at least two weeks of hospitalisation at the time of enrolment * Montreal Cognitive Assessment (Hungarian version) score of 18 or above, with education correction * Physically able to safely wear a head-mounted virtual reality display * Adequate corrected or uncorrected vision and hearing * Able to communicate in Hungarian * Stable psychiatric and cardiovascular condition, as determined from medical history and in consultation with the treating physician * Able to provide independent written informed consent Exclusion Criteria: * Epilepsy with recurrent seizures, or photosensitivity * Neurological condition associated with increased risk during virtual reality use, including Meniere's disease and significant carotid stenosis * Active psychosis, hallucinations, or severe depression with psychotic features * Open wound or skin lesion on the face, chronic neck pain, or spinal condition preventing safe use of the head-mounted display * Severe uncorrectable sensory impairment * Unstable psychotropic medication during the preceding eight weeks * Regular use of analgesic or psychotropic medication that may substantially affect perception of the experience * Active alcohol or substance use disorder within the past year * Refusal or inability to provide informed consent Enrolment is deferred, rather than excluded, in the presence of active delirium or infectious illness, until the condition resolves.

Home-Based tDCS for Depression in BPD

NCT06972368
Recruiting
Conditions Major Depressive Disorder (MDD), Borderl...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The present study aims to assess the feasibility of home-based tDCS in remote and urban areas (primary objective). The secondary aim is to obtain a preliminary assessment of the efficacy of 14 home-based tDCS sessions in reducing depressive symptoms in BPD patients with moderate to severe depressive episodes and BPD symptoms. Exploratory objectives include assessing the impact on neuropsychological and psychosocial functioning, anxiety, physical activity, sleep disorders, and addiction. Additionally, we aim to investigate the sociodemographic and clinical factors that are linked to the most favorable response to tDCS in addressing both depressive and BPD symptoms. We also aim to assess the feasibility of using a smartwatch as an outcome measure in this population. Finally, we intend to gather preliminary data on the effectiveness of an online psychoeducational program specifically designed for patients with BPD. Researchers will compare active tDCS to sham tDCS to see if active treatment is more effective in treating depression in this population. Participants will: * Receive 14 sessions of either active or sham tDCS over one week, delivered at home * Complete psychological and neurocognitive assessments at baseline, post-treatment, and at 6 weeks * Wear actigraphy monitors and complete questionnaires to assess sleep, physical activity, and other mental health outcomes This trial will also explore the feasibility of delivering tDCS in both urban and rural settings.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: tDCS — Description: Participants randomized to this arm will receive 14 sessions of home-based transcranial Direct Current Stimulation (tDCS), administered twice daily for 30 minutes over 7 consecutive days. Each session will use a 2mA current with a SNAPstrap™ montage targeting the left dorsolateral prefrontal cortex (F3) with the anode and the right DLPFC (F4) with the cathode. Sessions include a 30-second ramp-up and ramp-down. The total delivered charge will be 48 coulombs. Enhancement component: Each session will be paired with cognitive and emotional enhancement strategies: Emotion regulation script (DBT-inspired, personalized and pre-written based on a moderately dysregulated situation). Cognitive training via Lumosity, targeting executive functions and memory.
  • Procedure: Treatment as Usual (TAU) — Description: Throughout the study, participants are required to maintain stable pharmacological and psychotherapeutic regimens, defined as: No changes in medications or therapy for at least 6 weeks after tDCS initiation. TAU is provided by participants' regular treating physician or mental health professional, independent of the study team. TAU includes psychotropic medication, psychotherapy, and case management, as clinically indicated.
  • Procedure: Psychoeducation — All participants receive access to a structured online psychoeducation program before randomization. This includes: * Short videos (8-14 minutes each) covering BPD, depression, neuromodulation, therapeutic success factors, and tDCS. * Multiple-choice quizzes (MCQs) to ensure comprehension. * Delivered in French with English subtitles. Designed to improve understanding of BPD and associated treatments, including the rationale for tDCS.
  • Device: Sham-tDCS — Description: Participants randomized to this arm will receive 14 sessions of sham tDCS, with identical scheduling and device setup as the active condition. The session mimics real tDCS (same SNAPstrap montage, ramp-up and ramp-down of 30 seconds), but no current is delivered after the initial 30 seconds. Enhancement component: Participants follow the same emotional regulation script and Lumosity cognitive training during

Primary Outcomes

  • Feasibility and Acceptability of Home-Based tDCS (Baseline (Day 0), Week 1 (Day 7), Pre-intervention (immediately prior to first tDCS/sham), Post-intervention (within 1 day after of tDCS/sham), Month 3)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-01
Completion: 2027-06-01
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ciusss de L'Est de l'Île de Montréal
Contact Information
Study Contact:
Lionel Cailhol, MD, PhD
514-251-4000
lionel.cailhol.med@ssss.gouv.qc.ca
Lionel Cailhol, MD, PhD
lionel.cailhol.med@ssss.gouv.qc.ca
IUSMM
Interventions
  • Device: tDCS — Description: Participants randomized to this arm will receive 14 sessions of home-based transcranial Direct Current Stimulation (tDCS), administered twice daily for 30 minutes over 7 consecutive days. Each session will use a 2mA current with a SNAPstrap™ montage targeting the left dorsolateral prefrontal cortex (F3) with the anode and the right DLPFC (F4) with the cathode. Sessions include a 30-second ramp-up and ramp-down. The total delivered charge will be 48 coulombs. Enhancement component: Each session will be paired with cognitive and emotional enhancement strategies: Emotion regulation script (DBT-inspired, personalized and pre-written based on a moderately dysregulated situation). Cognitive training via Lumosity, targeting executive functions and memory.
  • Procedure: Treatment as Usual (TAU) — Description: Throughout the study, participants are required to maintain stable pharmacological and psychotherapeutic regimens, defined as: No changes in medications or therapy for at least 6 weeks after tDCS initiation. TAU is provided by participants' regular treating physician or mental health professional, independent of the study team. TAU includes psychotropic medication, psychotherapy, and case management, as clinically indicated.
  • Procedure: Psychoeducation — All participants receive access to a structured online psychoeducation program before randomization. This includes: * Short videos (8-14 minutes each) covering BPD, depression, neuromodulation, therapeutic success factors, and tDCS. * Multiple-choice quizzes (MCQs) to ensure comprehension. * Delivered in French with English subtitles. Designed to improve understanding of BPD and associated treatments, including the rationale for tDCS.
  • Device: Sham-tDCS — Description: Participants randomized to this arm will receive 14 sessions of sham tDCS, with identical scheduling and device setup as the active condition. The session mimics real tDCS (same SNAPstrap montage, ramp-up and ramp-down of 30 seconds), but no current is delivered after the initial 30 seconds. Enhancement component: Participants follow the same emotional regulation script and Lumosity cognitive training during
Study Locations (1 sites)
IUSMM, Montreal, Quebec H1N3M5 Canada
Eligibility Criteria
Inclusion Criteria: 1. To be aged between 18 and 65. 2. To meet the DSM-IV criteria for BPD. 3. To present a moderate depressive episode, defined as a MADRS score ≥ 20 (V1 and V3). 4. To be capable to consent to participate in the study. 5. To speak either French or English. 6. Participants must have a prescribing doctor or mental health professional responsible 7. To maintain a stable psychopharmacological and psychotherapeutic intervention. 8. To have access to internet an a smartphone. 9. To demonstrate proficiency in independently using a tDCS device. 10. To be able to pick up and return the remote tDCS device. Exclusion Criteria: \- 1. To have a history of Epilepsy. 2. To have a contraindication for tDCS Medical Devices. 3. To have a history of Cerebrovascular Surgery. 4. To present scalp Conditions Affecting tDCS Electrode Placement. 5. To have a history of bipolar disorder. 6. To present social or medical conditions limiting the autonomous use of remote tDCS. 7\. To be pregnant. 8. To be currently undergoing neuromodulation treatment. 9. To be currently using benzodiazepines.
Conditions Diabetes, Type 1 Diabetes
Phase NA
Enrollment 94
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This project will evaluate a telemedicine-delivered, Unified Protocol for Cognitive-Behavioral Therapy (UP-CBT) enhanced with continuous glucose monitor (CGM) review to target anxiety and depressive symptoms and glycemic control in adults with type 1 diabetes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Unified protocol for cognitive behavioral therapy (UP-CBT) — UP-CBT consists of approximately 16 individual sessions of CBT, conducted over the course of approximately 20 weeks. The UP-CBT consists of 5 core modules targeting negative emotionality and aversive reactions to emotional experiences. These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. The final module consists of relapse prevention. UP-CBT sessions will integrate a review of Continuous Glucose Monitoring (CGM) data and feedback will be provided by the therapist.
  • Device: Continuous Glucose Monitoring (CGM) — Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing anxiety and depressive disorders, along with self-management information and treatment options to discuss with providers will also be provided.

Primary Outcomes

  • Anxiety symptom severity (Baseline and midway through treatment (3 months), immediately post-treatment (5.5 months) and 9- and 12- months post-baseline)
  • Depressive symptom severity (Baseline and midway through treatment (3 months), immediately post-treatment (5.5 months) and 9- and 12- months post-baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-03-31
Completion: 2027-12
Eligibility
Age: 18 Years – 64 Years
Sex: ALL
Volunteers: false
Enrollment: 94 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Albert Einstein College of Medicine
Collaborators: Juvenile Diabetes Research Foundation, DexCom, Inc.
Principal Investigators:
  • Jeffrey Gonzalez, PhD (PRINCIPAL_INVESTIGATOR) - Albert Einstein College of Medicine
Contact Information
Study Contact:
Jeffrey Gonzalez, PhD
646-592-4506
jeffrey.gonzalez@yu.edu
Keyla Ordonez, BS
631-747-9325
keyla.ordonez@einsteinmed.edu
Todd Farchione, PhD
tfarchio@bu.edu
Boston University
Interventions
  • Behavioral: Unified protocol for cognitive behavioral therapy (UP-CBT) — UP-CBT consists of approximately 16 individual sessions of CBT, conducted over the course of approximately 20 weeks. The UP-CBT consists of 5 core modules targeting negative emotionality and aversive reactions to emotional experiences. These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. The final module consists of relapse prevention. UP-CBT sessions will integrate a review of Continuous Glucose Monitoring (CGM) data and feedback will be provided by the therapist.
  • Device: Continuous Glucose Monitoring (CGM) — Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing anxiety and depressive disorders, along with self-management information and treatment options to discuss with providers will also be provided.
Study Locations (2 sites)
Boston University, Boston, Massachusetts 02215 United States
Albert Einstein College of Medicine, The Bronx, New York 10461 United States
Eligibility Criteria
Inclusion Criteria: * Type 1 diabetes (T1D) duration ≥ 6 months * 18-64 years old * English- or Spanish-speaking * Anxiety or depressive mood disorder as per structured diagnostic interview. Exclusion Criteria: * Developmental or sensory disability interfering with participation * Current pregnancy * Bipolar disorders, psychotic disorders, severe eating disorders, severe substance abuse disorders, or acute suicidal risk or self-harm * Use of medications or recent medical procedures that would impact glycemic control or use of continuous glucose monitoring (CGM) over the study * Received cognitive behavioral therapy (CBT) in last year or plans to initiate CBT; (6) temporary exclusion for recent initiation of psychotropic medication - must be on a stable dose for 6 weeks prior to enrollment.
Conditions Obstructive Sleep Apnea-Hypopnea Syndrom...
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Obstructive sleep apnea-hypopnea syndrome (OSAS) is a common disorder in which repeated airway blockages during sleep lead to low oxygen levels, inflammation, and disrupted sleep. Many OSAS patients-both children and adults-experience problems with memory, attention, and mood, such as anxiety or depression. However, the exact molecular drivers of these brain changes are not fully understood. This observational study will enroll: Children (ages 2-18) and adults (\>18 years) with OSAS, as well as age- and sex-matched healthy volunteers. Clinical assessments: Children will undergo routine ENT examinations (including nasal endoscopy and X-rays); adults will have an overnight sleep study (polysomnography). All participants will complete questionnaires on sleepiness (e.g., ESS), mood (PHQ-9, GAD-7), and cognitive screening (MoCA for adults, age-appropriate scales for children). Sample collection: A small blood draw (3 mL) and, when applicable (e.g., adults undergoing surgery), a tiny subcutaneous fat biopsy. Saliva samples will also be collected. Laboratory tests: Measure expression levels of two key inflammatory pathway genes-EGR2 and NLRP3-in blood cells, saliva, and fat tissue using RNA sequencing, RT-qPCR, and Western Blot. Correlate these molecular markers with sleep parameters (AHI, oximetry), cognitive scores, and mood scores. Data analysis: Develop and validate machine-learning models that integrate data from multiple tissues to predict who is at highest risk for cognitive or mood disturbances.

Design

Study type: Observational Observational model: Other Time perspective: Retrospective

Interventions / Regimen

  • Procedure: EGR2/NLRP3 pathway activity — Peripheral blood collection \& PBMC isolation: Children: 3 mL venous blood drawn from the right antecubital vein preoperatively; Adults: 3 mL fasting venous blood drawn the morning after PSG. Collected in EDTA tubes; PBMCs separated via Ficoll-Paque density gradient. Flow cytometry: 1×10⁶ PBMCs stained for CD14/CD16, HLA-DR, CD11b, CD80/CD86, CD163/CD206. RNA extraction: Remaining PBMCs lysed in TRIzol and stored at -80 °C for RT-qPCR of EGR2, NLRP3, and downstream genes Serum/plasma: Within 1 h of collection, centrifuge at 400 × g for 10 min at 4 °C; 1 mL used for ELISA quantification of TNF-α, IL-6, IL-1β, CCL2, IL-17, CRP; remainder stored at -80 °C for future proteomic or metabolomic assays Saliva sampling \& processing: 2-3 mL unstimulated saliva expectorated into sterile tubes, kept at 4 °C, processed (centrifuged, aliquoted) within 2 h, then stored at -80 °C.
  • Procedure: fatty tissue — Subcutaneous fat biopsy (adults undergoing surgery): 100-200 mg obtained intraoperatively, placed in RNAlater at 4 °C for 24 h, then frozen at -80 °C for downstream RNA-seq, RT-qPCR, and Western blot analyses of EGR2, NLRP3, and related inflammatory markers

Primary Outcomes

  • Expression levels of EGR2 and NLRP3 in PBMCs, saliva, and subcutaneous fat tissue (Jul 2025 - Sep 2026)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-07-01
Completion: 2026-09-30
Eligibility
Age: 5 Years and older
Sex: ALL
Volunteers: true
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Contact Information
Study Contact:
Jiang, PHD,MD
13817719616
jianglaimz@sina.com
Jiang
+86 13817719616
jianglaimz@sina.com
Shanghai Xinhua hospital
Interventions
  • Procedure: EGR2/NLRP3 pathway activity — Peripheral blood collection \& PBMC isolation: Children: 3 mL venous blood drawn from the right antecubital vein preoperatively; Adults: 3 mL fasting venous blood drawn the morning after PSG. Collected in EDTA tubes; PBMCs separated via Ficoll-Paque density gradient. Flow cytometry: 1×10⁶ PBMCs stained for CD14/CD16, HLA-DR, CD11b, CD80/CD86, CD163/CD206. RNA extraction: Remaining PBMCs lysed in TRIzol and stored at -80 °C for RT-qPCR of EGR2, NLRP3, and downstream genes Serum/plasma: Within 1 h of collection, centrifuge at 400 × g for 10 min at 4 °C; 1 mL used for ELISA quantification of TNF-α, IL-6, IL-1β, CCL2, IL-17, CRP; remainder stored at -80 °C for future proteomic or metabolomic assays Saliva sampling \& processing: 2-3 mL unstimulated saliva expectorated into sterile tubes, kept at 4 °C, processed (centrifuged, aliquoted) within 2 h, then stored at -80 °C.
  • Procedure: fatty tissue — Subcutaneous fat biopsy (adults undergoing surgery): 100-200 mg obtained intraoperatively, placed in RNAlater at 4 °C for 24 h, then frozen at -80 °C for downstream RNA-seq, RT-qPCR, and Western blot analyses of EGR2, NLRP3, and related inflammatory markers
Study Locations (1 sites)
Shanghai Xinhua hospital, Shanghai, China
Eligibility Criteria
Inclusion Criteria: Children aged 2-18 years with obstructive snoring or sleep apnea features on initial ENT outpatient screening. Adults (\>18 years) with suspected OSAS in a sleep or respiratory clinic, presenting with chronic snoring, witnessed apneas, or daytime sleepiness, and without severe chronic heart, liver, kidney failure, psychiatric disorders, or pregnancy. Signed written informed consent by the participant or their legal guardian. Not currently enrolled in any other registered clinical trial. Exclusion Criteria: Presence of congenital craniofacial malformations. Severe heart, lung, liver, or kidney failure, or major neurological disease. Recent use of anti-inflammatory or other immunomodulatory medications. Current psychiatric disorder or pregnancy
Conditions Ischemic Stroke, Acute
Phase Not Applicable
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Through a multicenter prospective AIS cohort study, we analyze the potential association of human proteome, microbiome and metabolome alterations with AIS prognosis, searching for key proteins, differential organisms and metabolites, combining experimental data at multiple molecular levels with computational models, and establishing early prediction models through machine learning-based prediction algorithms. While closely tracking the recurrence of stroke in AIS patients, we evaluate the predictive value of human proteome, microbiome and metabolites for stroke recurrence through a nested case-control study, which provides key reference information for exploring the unknown residual risk of AIS recurrence.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: microbiome; metabolomics; proteomics — post-stroke change of microbiome; metabolomics; proteomics

Primary Outcomes

  • Incidence of new cardiovascular events and death (within 12 months after onset)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-01-30
Completion: 2028-12-31
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: Not specified
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nanfang Hospital, Southern Medical University
Contact Information
Study Contact:
Jia Yin, M.D
13802964883
jiajiayin@139.com
Weike Hu, M.D
18326349212
weike946@gmail.com
Jia Yin, M.D
13802964883
jiajiayin@139.com
Nanfang Hospital,Southern Medical University
Interventions
  • Other: microbiome; metabolomics; proteomics — post-stroke change of microbiome; metabolomics; proteomics
Study Locations (1 sites)
Nanfang Hospital,Southern Medical University, Guangzhou, Guangdong 510515 China
Eligibility Criteria
Inclusion Criteria: 1. Meet the diagnostic criteria of AIS according to the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018 2. Aged 18 to 75 years old 3. Stroke within 7 days of onset 4. Sign informed consent, provide relevant medical history information and provide biological specimens Exclusion Criteria: 1. Severe impairment of consciousness (awareness score of NIHSS\>1) 2. History of stroke within 12 months 3. Severe systemic disease including malignancy 4. ALT or AST\> 2 times the upper limit of normal or severe liver disease 5. creatinine \> 1.5 times the upper limit of normal or severe kidney disease 6. History of long-term drinking, drug use, and chemical poisoning (e.g., pesticide poisoning); Note: Long-term alcohol consumption, usually more than 5 years, over 40 g/day of alcohol for men and 20 g/day for women, or a history of heavy alcohol consumption within 2 weeks, over 80 g/day of alcohol 7. History of intestinal tumors, irritable bowel syndrome or inflammatory bowel disease or confirmed in the hospital 8. Unable to collect a stool specimen within 4 days of admission 9. Assessed to be unsuitable for participation in this study by the investigator

The OBSERVE Protocol

NCT06725277
Recruiting
Conditions Major Depression Disorder
Phase Not Applicable
Enrollment 450
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This observational protocol is intended to provide long-term follow-up data on patients initiating or continuing treatment with either Spravato® or IV ketamine. This can provide us information on the patient acceptability and satisfaction, patterns of use, long-term effectiveness, and safety of the two approaches. This 5-year, 6-site study will enroll 450 total patients. The sites will comprise 3 academic medical centers and 3 community psychiatric practices.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Spravato — Intranasal esketamine
  • Drug: IV Ketamine — IV ketamine

Primary Outcomes

  • TSQM-9 (baseline to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-01-21
Completion: 2029-12
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 450 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yale University
Collaborators: Patient-Centered Outcomes Research Institute
Principal Investigators:
  • Samuel Wilkinson, MD (PRINCIPAL_INVESTIGATOR) - Yale University
Contact Information
Study Contact:
Cindy Voghell
203-737-4784
cynthia.voghell@yale.edu
Lisa Harding, MD
203-701-9737
Trials@DepressionMD.com
Mood Institute
Lisa Harding, MD
Mood Institute
Interventions
  • Drug: Spravato — Intranasal esketamine
  • Drug: IV Ketamine — IV ketamine
Study Locations (8 sites)
Mood Institute, Milford, Connecticut 06461 United States
Yale School of Medicine, New Haven, Connecticut 06512 United States
Emory University, Atlanta, Georgia 30322 United States
University of Michigan, Ann Arbor, Michigan 48104 United States
LifeStance Health, Moore, Oklahoma 73160 United States
Athena Care, Nashville, Tennessee 37228 United States
Houston Center for Advanced Psychiatric Treatment, Bellaire, Texas 77401 United States
Seattle NTC, Seattle, Washington 98104 United States
Eligibility Criteria
Inclusion Criteria: In order to be eligible to participate in this study, an individual must meet the following criteria: 1. Recently started treatment (within 75 days of screening visit) with IV ketamine or Spravato® as prescribed by a clinician for the treatment of moderate to severe (based on an initial MADRS score ≥ 25) TRD (refractory to two or more antidepressant trials) without psychotic features and having appropriate baseline measures collected before starting treatment. These patients are referred to as treatment-continuing subjects. OR 2. Scheduled to receive standard clinical treatment with IV ketamine or Spravato® as prescribed by a clinician for the treatment of moderate to severe (based on an initial MADRS score ≥ 25) TRD (refractory to two or more antidepressant trials) without psychotic features. These patients are referred to as treatment-initiating subjects. In addition, in order to be eligible, an individual must meet all of the following additional criteria: 3. Adult ages 18 or older 4. Provision of signed and dated informed consent form prior to any study procedures 5. Stated willingness to comply with all study procedures and availability for the duration of the study Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Diagnosis of bipolar disorder or psychotic disorder (i.e., schizophrenia, schizoaffective disorder) 2. Other psychiatric comorbidities are permitted so long as depression is the predominant diagnosis 3. Active or recent (within 12 months) substance use disorder (other than nicotine)
Conditions Depression in Adults, Anxiety Disorder G...
Phase PHASE1
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This project aims to implement and evaluate a dyadic intervention (i.e., acceptance commitment therapy) for persons with AD/ADRD and their care partners. We hypothesize the intervention will be feasible, acceptable, and show preliminary efficacy of the dyadic interveniotns.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Acceptance Commitment Therapy — Acceptance and Commitment Therapy (ACT) is a form of cognitive-behavioral therapy that aims to enhance psychological flexibility through six core processes: acceptance, cognitive defusion, being present, self-as-context, values clarification, and committed action. Rather than attempting to eliminate difficult thoughts and feelings, ACT encourages individuals to accept them while committing to behavior changes consistent with their personal values.

Primary Outcomes

  • Patient Health Questionnaire-9 (6 weeks)
  • Geriatric Depression Short From (6 Weeks)
  • The Generalized Anxiety Disorder-7 (6 weeks)
  • General Anxiety Scale-10 (6 Weeks)
  • Pre-death grief-12 (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-04-01
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Texas Tech University
Contact Information
Study Contact:
Jonathan Singer, Ph.D.
17757228066
jonsinge@ttu.edu
Jonathan Singer, Ph.D.
7757228066
jonsinge@ttu.edu
Texas Tech University Plaza Building
Interventions
  • Behavioral: Acceptance Commitment Therapy — Acceptance and Commitment Therapy (ACT) is a form of cognitive-behavioral therapy that aims to enhance psychological flexibility through six core processes: acceptance, cognitive defusion, being present, self-as-context, values clarification, and committed action. Rather than attempting to eliminate difficult thoughts and feelings, ACT encourages individuals to accept them while committing to behavior changes consistent with their personal values.
Study Locations (1 sites)
Texas Tech University Plaza Building, Lubbock, Texas 79409-2051 United States
Eligibility Criteria
Inclusion Criteria Inclusion (person with MCI or MNCD): * 18+ * MMSE= 21-27 * Able to communicate in English Inclusion (care partner): * 18+ * Identifies as a care partner of a person with MNCD * Able to communicate in English * MMSE= 28-30 * Is a family member or friend of the person with MNCD Exclusion Criteria Exclusion (person with MCI or MNCD): * Currently in an intervention for reducing anxiety or depression related to their dementia * MMSE= 28+ or less than 21 Exclusion (care partner): * MMSE= \<28 * Is a formal (paid) caregiver
Conditions Suicide, Suicidal Ideation, Depression
Phase PHASE1
Enrollment 50
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Ketamine — Patients will receive 0.2mg/kg of IV ketamine

Primary Outcomes

  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] (2 hours)
  • Provider and Nursing Attitudes toward use of Ketamine for Suicidal Patients in the ED [Feasibility] (2 hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-05-01
Completion: 2027-04
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Lindsay Maguire, MD
Contact Information
Study Contact:
Lindsay Maguire, MD
913-588-3580
lmaguire@kumc.edu
Lucas Lemar
llemar@kumc.edu
Tyler Kjorvestad, MD
tkjorvestad@kumc.edu
University of Kansas Strawberry Hill Campus
Interventions
  • Drug: Ketamine — Patients will receive 0.2mg/kg of IV ketamine
Study Locations (2 sites)
University of Kansas Strawberry Hill Campus, Kansas City, Kansas 66101 United States
University of Kansas Medical Center Emergency Department, Kansas City, Kansas 66160 United States
Eligibility Criteria
Inclusion Criteria: * Acutely Suicidality ("yes" answer to any of items 4 or 5 on C-SSRS "Suicidal Ideation" category) * Require inpatient stabilization for SI or actions based on clinical observation and interview * Are accepted for psychiatric stabilization at the University of Kansas Medical Center's Strawberry Hill campus * Have a Glasgow Coma Score (GCS) of 15 * Age 18-65 Exclusion Criteria: * Current or past history of psychosis * Current or recent (past 4 weeks) symptoms of mania/hypomania as defined by Young Mania Rating Scale (YRMS) score of 12 or greater * History of ketamine use disorder * History of liver transplant * Pregnancy or breastfeeding * Imprisonment or inability to consent * Positive urine drug screen or serum alcohol level * Hypertension (SBP \> 160 or DBP \> 100 before administration of ketamine) * Hypotension (SBP \< 90) * Presence of acute medical condition requiring admission to medical service * Allergy, intolerance, or previous adverse reaction to ketamine * Patient has 8+ lifetime ketamine exposures * The treating physician determines that the patient is not a good candidate for the study (e.g. medical condition/procedure, medication that would contradindicate ketamine treatment)
Conditions Depressive Disorder, Treatment-Resistant...
Phase PHASE2
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to to evaluate the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or normal saline infusion utilizing fMRS, and change in peripheral GABA and Glu levels from baseline to 24-hr postinfusion utilizing LCMS, with baseline to 24-hr post-infusion change in depression (MADRS) in 30 TRD adults.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Ketamine — The subjects will receive 1:1 single IV racemic ketamine (dosed @0.5 mg/kg actual body weight) (n=15) 40-min infusion in an MRI scanner, followed by an optional open-label ketamine infusion (available to everyone) 1-7 days after the initial treatment
  • Drug: Normal Saline — The subjects will receive 1:1 single IV normal saline/placebo (n=15) 40-min infusion in an MRI scanner, followed by an optional open-label ketamine infusion (available to everyone) 1-7 days after the initial treatment

Primary Outcomes

  • Peak (% change from baseline) Anterior Cingulate Cortex metabolites (Gamma-Aminobutyric Acid and Glutamate) (Baseline to the end of 40-minute infusion)
  • Change in peripheral Gamma-Aminobutyric Acid and Glutamate levels (Baseline to the end of 40-minute infusion)
  • Change in the Montgomery Asberg Depression Rating Scale (Baseline to 24-hours post-infusion)
  • Correlation between the percent change in central (anterior cingulate cortex) Gamma-Aminobutyric Acid and Glutamate levels and the change in depression severity measured using the Montgomery-Åsberg Depression Rating Scale (Baseline to the end of 40-minute infusion for GABA and Glu. Baseline to 24 hours post-infusion for MADRS)
  • Correlation between the percent change in serum Gamma-Aminobutyric Acid and Glutamate levels and the change in depression severity measured using the Montgomery-Åsberg Depression Rating Scale (Baseline to the end of 40-minute infusion for serum GABA and Glu. Baseline to 24 hours post-infusion for MADRS)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-02-10
Completion: 2027-12-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Collaborators: National Center for Advancing Translational Sciences (NCATS)
Principal Investigators:
  • Balwinder Singh, M.D., M.S. (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Nicole Reinicke
507-422-1835
reinicke.nicole@mayo.edu
Balwinder Singh
Mayo Clinic in Rochester
Interventions
  • Drug: Ketamine — The subjects will receive 1:1 single IV racemic ketamine (dosed @0.5 mg/kg actual body weight) (n=15) 40-min infusion in an MRI scanner, followed by an optional open-label ketamine infusion (available to everyone) 1-7 days after the initial treatment
  • Drug: Normal Saline — The subjects will receive 1:1 single IV normal saline/placebo (n=15) 40-min infusion in an MRI scanner, followed by an optional open-label ketamine infusion (available to everyone) 1-7 days after the initial treatment
Study Locations (1 sites)
Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria: * Ability to provide informed consent * Meets diagnostic criteria for major depressive disorder without psychotic features per the SCID DSM-IV-TR * PHQ-9 total score ≥ 15 at screening * Treatment-resistant depression, as defined by failure of at least two previous antidepressant treatments within the current depressive episode. Failed antidepressant treatments can include pharmacotherapy for depression at an adequate dose for at least 8 weeks, trial of transcranial magnetic stimulation (TMS) or an acute series of at least 6 administrations of electroconvulsive therapy (ECT) * Ability to pass a comprehension assessment test related to effects of ketamine and trial objectives and criteria Exclusion Criteria: * Inability to speak English * Inability to provide consent or have a legal guardian * Patients with a BMI \> 40 kg/m2. * Personality disorder being the primary diagnosis * Diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or active psychotic symptoms * Active post-traumatic stress disorder symptoms based on clinical assessment * Ongoing prescription of \> 2 mg lorazepam equivalents (total) daily, or morning dosing of any benzodiazepine at the time of assessment * Medications known to affect glutamate (i.e., Riluzole, Carbamazepine) or GABA (zaleplon, zolpidem, zopiclone, Valproate, Gabapentin, Pregabalin, tiagabine, and vigabatrin) are prohibited within two weeks prior to administration of study drug and at least 24 hours after last dose of study drug * Monoamine Oxidase Inhibitors (MAOIs) are prohibited two weeks prior to administration of study drug * Opioid antagonists (naltrexone, naloxone, nalmefene, methylnaltrexone, buprenorphine and naloxone combination) are prohibited within two weeks prior to administration of study drug and at least 24 hours after last dose of study drug * CYP3A4 inducers carbamazepine and modafinil are prohibited within two weeks prior to administration of study drug and at least 24 hours after last dose of study drug. * Currently undergoing TMS, vagal nerve stimulation, or deep brain stimulation as either an acute or maintenance treatment of depression * ECT in the past 6 months * Any active or unstable medical condition judged by the study psychiatrist as conferring too great a level of medical risk to allow inclusion in the study * A history of bleeding in the brain * Arteriovenous malformation or a history of aneurysm * Use of methamphetamine, cocaine, or cannabis. Abuse of stimulant (s) within the prior 12 months * Any current substance use disorder (excluding nicotine and caffeine). Note: Persons will be allowed to enroll in this study if their substance use is in complete (not partial) and sustained (\&gt; 1 year) remission * History of traumatic brain injury that resulted in loss of consciousness with brain bleeding * History of tonic-clonic (grand mal) seizures * Developmental delay, intellectual disability, or intellectual disorder * Clinical or self-reported diagnosis of delirium, encephalopathy, or related clinical diagnosis within the prior 12 months * Minor or Major Neurocognitive disorder * Received ketamine treatment for depression within the prior 2 months * History of either poor antidepressive response to or poor tolerability of ketamine (any route of administration) when previously administered * History of hypothyroidism unless taking a stable dose of thyroid medication and asymptomatic for 3 months * Hepatic insufficiency (2.5 X ULN for AST or ALT) within 3 months of consent, past liver transplant recipient, and/or clinical diagnosis of cirrhosis of the liver * Gastroesophageal reflux disease that is poorly managed * A diagnosis of Complex Regional Pain Syndrome (CRPS) * Pregnancy, or nursing * History of claustrophobia with active symptoms that would interfere with the MRI * Any contraindication to MRI safety questionnaire * Poorly controlled hypertension.
Conditions Parents, Children With Disabilities, Str...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate the feasibility, usability, and preliminary benefits of implementing ACT Together for parents of children with disabilities in pediatric outpatient clinics. ACT Together includes six self-paced, web-based modules and brief weekly one-on-one coaching sessions led by a trained occupational therapist. The program is based on acceptance and commitment therapy (ACT), which teaches practical skills to help people handle stress and difficult thoughts or feelings while taking steps toward what matters to them. The main questions this study aims to answer are: * Can parents and occupational therapists complete the study activities as planned (e.g., module completion, coaching sessions, and surveys)? * Is the program usable and acceptable/appropriate/feasible to implement in this setting? * Do parents show improvements in mental health and coping-related outcomes after participating in the program? * What are the experiences and perspectives of parents and therapists regarding the program? Parents as participants will: * Complete six self-paced web-based modules and brief weekly individual phone coaching sessions with a trained occupational therapist working in pediatric outpatient clinics. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experiences and perspectives on the program. Occupational therapists as participants will: * Complete therapist training materials and deliver brief individual phone coaching sessions to parent participants, including completing a post-session checklist. * Complete brief online questionnaires before starting and after delivering the program. * Take part in one online interview about their experiences and perspectives on the program.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: ACT Together — ACT Together includes six self-paced, weekly web-based ACT modules and six brief phone coaching sessions delivered after each module by a trained occupational therapist.

Primary Outcomes

  • Enrollment rate (During the recruitment period (up to approximately 6 months))
  • Retention (Baseline through post-intervention (approximately 7-8 weeks))
  • Web-based module completion (Baseline through post-intervention (approximately 7-8 weeks))
  • Coaching session completion (Baseline through post-intervention (approximately 7-8 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-18
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of South Florida
Collaborators: American Occupational Therapy Foundation
Principal Investigators:
  • Areum Han, PhD (PRINCIPAL_INVESTIGATOR) - University of South Florida
Contact Information
Study Contact:
Areum Han, PhD
813-396-0524
areumhan@usf.edu
Jeremy Jenkins, MS
813-396-0524
jeremyjenkins@usf.edu
Areum Han, PhD
813-396-0524
areumhan@usf.edu
University of South Florida
Interventions
  • Behavioral: ACT Together — ACT Together includes six self-paced, weekly web-based ACT modules and six brief phone coaching sessions delivered after each module by a trained occupational therapist.
Study Locations (1 sites)
University of South Florida, Tampa, Florida 33612 United States
Eligibility Criteria
Inclusion Criteria (Parents of children with disabilities): 1. Community-dwelling adults (aged ≥18 years) with primary caregiving responsibility for a child with disabilities (aged \<18 years) who is enrolled in a participating clinic; 2. Expected to use services at the participating clinic at least once per week over the next three months; 3. Willing to learn strategies to cope with emotions and thoughts; and 4. Have access to a web-enabled device (e.g., smartphone, tablet, laptop, or desktop) with reliable internet access at home or in a public space (e.g., library). Exclusion Criteria (Parents of children with disabilities): 1. Cognitive, physical, sensory impairments, or language barriers (non-English speaking) that would impede participation; 2. Suicidal intent or suicide attempt(s) within the past six months; 3. Participation in another parent support research study at the time of recruitment; or 4. More than three hospitalizations of either the parent or child within the past year, or other serious health concerns that would interfere with program engagement. Inclusion Criteria (Occupational therapists): 1. Be willing to participate in training, program implementation, and study evaluations; and 2. Currently work in a pediatric clinic that serves at least 15 children who attend the clinic at least once per week. Exclusion Criteria (Occupational therapists): N/A

Neurosurgical Outcome Network

NCT06724029
Recruiting
Conditions Aneurysms, Arteriovenous Malformations, ...
Phase Not Applicable
Enrollment 4500
Locations 27 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The evaluation of neurosurgical outcomes varies from center to center, and the predictive factors that determine these outcomes are not fully known or shared. This study aims to assess outcomes and their predictors using measures agreed upon by the participating centers. Standardizing the evaluation of outcomes and predictors improves the quality of research, allows for data comparison, and facilitates a "common language" in routine clinical practice. Most importantly, it influences therapeutic decisions in various neurosurgical conditions. Clinically, the identified predictors can also be used during preoperative assessments to provide more precise guidance to patients undergoing surgery.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Primary Outcomes

  • Collect data (5 years)
  • Collection data (5 years)
  • Collection data (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-12-05
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 4500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Contact Information
Study Contact:
Paolo Ferroli, MD
+39 02 2394 2411
paolo.ferroli@istituto-besta.it
Morgan A Broggi, MD
+39 02 2394 2411
morgan.broggi@istituto-besta.it
Giuseppe Barbagallo, MD
095 - 479 4473
giuseppebarbagal@hotmail.com
Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco"
Interventions
N/A
Study Locations (27 sites)
1. ASST Papa Giovanni XXIII, Bergamo, BG 24127 Italy
Spedali Civili Brescia, Brescia, BS 25123 Italy
Fondazione Poliambulanza Istituto Ospedaliero, Brescia, BS 25124 Italy
Ospedale Moriggia Pelascini, Gravedona, Como 22015 Italy
ASST Lariana, Ospedale S. Anna, Como, CO 22100 Italy
ASST Cremona, Cremona, CR 26100 Italy
Fondazione IRCCS San Gerardo dei Tintori, Monza, MB 20900 Italy
Fondazione IRCCS Policlinico San Matteo, Pavia, PV 27100 Italy
ASST della Valtellina ed Alto Lario, Sondrio, SO 23100 Italy
Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco", Catania, Italy
Eligibility Criteria
Inclusion Criteria: * Neuro-oncological pathology: supratentorial and subtentorial tumors, intra and extra axial tumors excluding the skull base (anterior, middle and posterior fossa; sellar and parasellar region) * Basicranial pathology: tumors originating from the anterior cranial fossa, middle cranial fossa and posterior cranial fossa, sellar region with or without supratentorial/parasellar development. * Vascular pathology: aneurysms, AVMs, cavernomas, other pathologies (Moyamoya disease, dural fistulas, nontraumatic hematomas) * Traumatic pathology: diffuse damage (nonvisible diffuse damage, diffuse damage, diffuse damage with edema, diffuse damage with shift) and focal damage (acute/subacute/chronic subdural hematoma, extradural hematoma, subarachnoid hemorrhage, intraparenchymal hematoma, fractures); hydrocephalus. The inclusion criterion for chronic subdural hematoma is recent bleeding for TBI with CT finding of chronic subdural hematoma candidate for evacuation surgery. * Spinal pathology: degenerative cervical (anterior/posterior), myelopathic, and trauma pathology; instrumented, uninstrumented thoracolumbar pathology (disc pathology, canal pathology), and trauma pathology; oncologic spinal pathology. * Functional pathology: Parkinson's disease, spasticity, trigeminal neuralgia, craniofacial pain/algia, neuropathic pain, tremor, dystonias, obsessive compulsive disorder, drug-resistant epilepsies, depression. Normotensive hydrocephalus. * Peripheral nervous system pathology: peripheral nerve compression syndromes, peripheral nerve and plexus tumors, brachial plexus and peripheral nerve trauma (contusion and section) * Malformative pathology: Chiari malformation type 1 and craniostenoses including both those framed in malformative syndromes and those not framed in malformative syndromes (monosutural craniostenoses: trigonocephaly, plagiocephaly, scaphocephaly; multisutural craniostenoses). Malformative hydrocephalus. * For cognitive and psychological assessment: age 18 years or older; adequate understanding of Italian language; diagnosis of glioma, meningioma, vascular pathology, spinal pathology Exclusion Criteria: * For cognitive and psychological assessment: patients with psychiatric diseases in history and/or taking psychotropic drugs; presence of overt cognitive decline (not due to the injury) in history; patients younger than 18 years old.